Fresenius SE & Co. KGaA
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Fresenius SE & Co. KGaA
The emergence and rapid spread of the Omicron variant has kept COVID-19 firmly in the headlines but the biopharma industry has had plenty on its plate on top of tackling the pandemic. Scrip has taken a look back at five of the biggest non-COVID-19 story themes of 2021 in no particular order.
Merging with a special purpose acquisition corporation is a viable funding tool, but it may not be the best choice for drug developers far from key milestones.
BioMarin teams with Skyline on gene therapies for cardiovascular disease. Myrtelle discloses licensing of gene therapy for Canavan disease from Pfizer earlier in 2021.
Although ANG-3777, partnered with Vifor, missed its primary endpoint in cardiovascular surgery patients at risk for acute kidney injury, the companies will consider a path forward based on a renal events measure.
- In Vitro Diagnostics
- Medical Devices
- Other Names / Subsidiaries
- APP Pharmaceuticals, Inc.
- Asia Renal Care Ltd.
- Fresenius Kabi Pharmaceuticals Holding, Inc.
- Fresenius Medical Care
- Fresenius Medical Group AG
- Vifor-Fresenius Medical Care Renal Pharma Ltd. (VFMCRP)
- Xenios AG